Caliway Biopharmaceuticals L Overview
Get informed when a big investor buys or sells
+ Follow-3.03%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, 6919.TW shows a ROE of -3.03%. That is below the Healthcare sector average of 13.26%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 13.26%. Caliway Biopharmaceuticals L is at -3.03%, which is lower that average. That is roughly 122.9% below the sector mean. Use the comparison chart on this page to see how 6919.TW stacks up against individual peers as well.
Check the historical chart to see whether 6919.TW's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Caliway Biopharmaceuticals L with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Caliway Biopharmaceuticals L's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -3.03%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 13.26%, while 6919.TW is at -3.03%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
